Listed by the USPTO as MOU, LIYUAN
Tech Center 1600 • Art Units: 1624 1628 1629 1645
This examiner grants 44% of resolved cases
MOU, LIYUAN handles applications in Tech Center 1600 and Art Unit 1624. The profile contains 121 resolved cases, with a 43.8% allowance rate and a median of 1131 days to allowance. Interviews correspond to a 59.9% lift in allowance outcomes, making examiner interaction a significant planning consideration.
Frequent applicants include Empathbio Inc., Board of Regents of the University of Texas System, and Arxada LLC. The leading firms are FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, COOLEY LLP, and DORITY & MANNING, P.A. The positive interview association should be evaluated alongside the moderate allowance rate and extended median timeline.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19219972 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | Non-Final OA | ANTECIP BIOVENTURES II LLC |
| 17284363 | COMBINATION OF AN UROLITHIN WITH AN IMMUNOTHERAPY TREATMENT | Non-Final OA | Amazentis SA |
| 17595446 | DIETARY BUTYRATE AND ITS USES | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 18679934 | 6-PYRIMIDIN-ISOINDOLE DERIVATIVE AS ERK1/2 INHIBITOR | Non-Final OA | OTSUKA PHARMACEUTICAL CO., LTD. |
| 18699069 | COMPOSITION CONTAINING SESAMIN AND ERGOTHIONEINE OR SALT THEREOF | Non-Final OA | SUNTORY HOLDINGS LIMITED |
| 18576595 | Antibacterial Compound | Non-Final OA | LG Chem, Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy43.8% of resolved applications examined by Liyuan Mou were allowed (121 resolved cases), compared with 54.6% across Art Unit 1624 over the last five years.
This examiner's interview lift is +59.9 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Liyuan Mou took 1,131 days on average from filing to allowance.
Liyuan Mou examines applications in Art Unit 1624 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
